Association of a beta-2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation by Jocken, J.W. et al.
  
 
Association of a beta-2 adrenoceptor (ADRB2) gene
variant with a blunted in vivo lipolysis and fat
oxidation
Citation for published version (APA):
Jocken, J. W., Blaak, E. E., Schiffelers, S. L. H., Arner, P., van Baak, M. A., & Saris, W. H. (2007).
Association of a beta-2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat
oxidation. International Journal of Obesity, 31(5), 813-819. https://doi.org/10.1038/sj.ijo.0803499
Document status and date:
Published: 01/01/2007
DOI:
10.1038/sj.ijo.0803499
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
ORIGINAL ARTICLE
Association of a beta-2 adrenoceptor (ADRB2) gene
variant with a blunted in vivo lipolysis and fat oxidation
JWE Jocken1, EE Blaak1, S Schiffelers1, P Arner2, MA van Baak1 and WHM Saris1
1Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht, Maastricht University, Maastricht,
The Netherlands and 2Department of Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
Background and aims: Obesity is associated with a blunted b-adrenoceptor-mediated lipolysis and fat oxidation. We
investigated whether polymorphisms in codon 16, 27 and 164 of the b2-adrenoceptor gene (ADRB2) and exon 10 of the
G protein b3-subunit gene (GNB3) are associated with alterations in in vivo lipolysis and fat oxidation.
Design and methods: Sixty-five male and 43 female overweight and obese subjects (body mass index (BMI) range:
26.1–48.4 kg/m2) were included. Energy expenditure (EE), respiratory quotient (RQ), circulating free fatty acid (FFA) and
glycerol levels were determined after stepwise infusion of increasing doses of the non-selective b-agonist isoprenaline (ISO).
Results: In women, the Arg16 allele of the ADRB2 gene was associated with a blunted increase in circulating FFA, glycerol and a
decreased fat oxidation during ISO stimulation. In men, the Arg16 allele was significantly associated with a blunted increase in
FFA but not in glycerol or fat oxidation.
Conclusion: These results suggest that genetic variation in the ADRB2 gene is associated with disturbances in in vivo
b-adrenoceptor-mediated lipolysis and fat oxidation during b-adrenergic stimulation in overweight and obese subjects; these
effects are influenced by gene–gender interactions.
International Journal of Obesity (2007) 31, 813–819. doi:10.1038/sj.ijo.0803499; published online 28 November 2006
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Introduction
Obesity is characterized by increased circulating free fatty
acid (FFA) concentrations and increased triglyceride (TG)
storage within adipose tissue. In vivo studies have shown that
the development or maintenance of increased adipose tissue
stores might be promoted by a blunted lipolytic response
and fat oxidation after b-adrenergic stimulation or exercise
in obese or obese type 2 diabetic subjects.1–4 This blunted
b-adrenoceptor-mediated lipolysis and fat oxidation persisted
after weight reduction, indicating that this disturbance
may be an early, even primary factor, in the develop-
ment or maintenance of increased adipose stores.1 There
are indications that the blunted b-adrenergically mediated
lipolysis in obesity may be related to an impaired function or
a reduced number of adipocyte beta-2 (b2) adrenoceptors.
5,6
b2-Adrenoceptors are stimulatory G-protein-coupled (Gs)
receptors. The b2-adrenoceptor (ADRB2) gene is encoded by
an intronless gene on chromosome 5q31–q32.7,8 Several
polymorphisms of the human ADRB2 gene have been
described.9,10 Among these, three common single-nucleotide
polymorphisms (SNPs) result in the substitution of an amino
acid. One is located at codon 16, substituting arginine
for glycine (Arg16Gly). The other one is located at codon 27,
substituting glutamic acid for glutamine (Gln27Glu). Both
variants are located in the extracellular amino-terminal
region of the receptor and alter cellular trafficking and
desensitization of the receptor.11 Previous studies have
reported associations between codons 16 and 27 polymorph-
isms and obesity, insulin resistance and hypertension.12–22
Finally, the substitution of isoleucine for threonine at codon
164 (Thr164Ile), in the receptor transmembrane-spanning
domains, alters agonist binding and decreases coupling
of the Gs protein to the receptor.
23,24 There is evidence from
in vitro studies that some of these receptor variants might
be important for catecholamine-induced adipocyte lipolysis
in humans.16,25
Furthermore, polymorphisms in G proteins involved in
catecholamine signaling may alter corresponding receptor
and hormone function. Recently, a common polymorphism
substituting a cytosine for a thymine at position 825
(C825T) in exon 10 of the G-Protein b3-subunit (GNB3) gene
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(chromosome 12p13), coding an isoform of the G protein
b subunit (Gb3), has been identified.
26 Gs deficiency is also
observed in obesity and the C825T polymorphism is
associated with obesity and hypertension in both white
and non-white populations.27–34 In vitro studies indicated
that the 825T variant of Gb3 in its homozygous form was
associated with a decreased amount of Gb3 in fat cells,
thereby inhibiting signaling through b1-, b2- and a2-adreno-
ceptors, resulting in decreased catecholamine action and
blunted lipolysis in isolated subcutaneous adipocytes of male
and female obese subjects.35
Thus, there are indications that polymorphisms in the
ADRB2 gene and the GNB3 gene may be related to an
impaired in vitro lipolytic response. So far, however, few
in vivo lipolysis studies on these polymorphisms have been
performed. For this reason, the present study investigated
the effect of genetic variation in the ADRB2 and the GNB3
gene on in vivo lipolysis and fat oxidation in overweight and
obese subjects.
Methods
Subjects
The study group consisted of 108 overweight and obese
(BMI range: 26.1–48.4 kg/m2) subjects (43 F/65 M). Twenty-
four overweight subjects (BMI between 25 and 29.9 kg/m2;
11 F/13 M) and 84 obese subjects (BMI429.9 kg/m2;
32 F/52M) were included. The basic selection criteria were
age 20–50 years and BMI425 kg/m2. Exclusion criteria were
weight change 43 kg within 3 months before the study
started, drug-treated hypertension, diabetes or hyperlipide-
mia, thyroid disease, surgically treated obesity, pregnancy,
alcohol or drug abuse and participation in other simulta-
neous ongoing trials. All subjects were recruited by means
of an advertisement in a local newspaper. All subjects
were in good health as assessed by medical history and
physical examination and were not taking any medication.
A normal resting electrocardiogram (ECG) and blood
pressure were a prerequisite for participation. The study
protocol was reviewed and approved by the Medical
Ethical Review Committee of Maastricht University. The
subjects were informed in detail about the investigation
and their consent was obtained before participating in
the study.
Anthropometric measurements
Body weight was determined on an electronic scale, accurate
to 0.1 kg. Waist and hip circumference measurements to
the nearest 1 cm were made with the subjects standing
upright. BMI was calculated as body weight in kilograms
divided by squared height in meters. Body density was
obtained by underwater weighing with residual pulmonary
volume measurement by the helium dilution method
(Volugraph 2000, Mijnhardt) and was converted to percent
body fat using the equation of Siri.36 Fat mass (FM) and
fat-free mass (FFM) were calculated from the percent body fat
and body weight.
Study design
The subjects arrived at the laboratory at 0800 after an
overnight fast (of at least 12 h) by car or public transport.
They were studied while resting supine on a comfortable bed
in a room kept at 23–251C. At the beginning of the
experiment, a catheter was inserted into a forearm vein for
blood sampling. A second catheter was inserted into the
contralateral arm for infusion of the non-selective b-agonist
isoprenaline (ISO). Thirty minutes after insertion of the
catheters, the measurement protocol started. Energy expen-
diture and substrate oxidation were measured during the
entire period with an open-circuit ventilated hood system.
After 30 min, blood was sampled for baseline measurements
and genetic analysis. Following the 30-min baseline
period, ISO infusion started at increasing concentrations
of 6, 12 and 24 ng . kg FFM1 . min1, each dose for 30 min.
At the end of each infusion period, venous blood samples
were taken, centrifuged and stored at 801C until further
analysis. During ISO infusion, heart rate was kept under
close observation by means of an ECG. When the heart
rate increased by more than 30 beats/min above baseline
or in case of an irregular heart rhythm, ISO infusion
was stopped.
Genetic analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes by digestion with protein K followed by phenol/
chloroform extraction. Amplification of the relevant
segments of the ADRB2 and GNB3 genes was performed by
polymerase chain reaction (PCR) as previously described.16,35
PCR products were digested at 371C for 1 h using BsrDI,
ItaI, MnlI or BseDI. The digested fragments were visualized
using ethidium bromide staining and UV-transmitted light.
Finally, we evaluated the accuracy of the restriction fragment
length polymorphism (RFLP) method by direct sequencing
of random samples and got 100% agreement. In addition,
two persons independently evaluated samples and identical
results were obtained.
Biochemical analysis
Whole blood was collected in tubes containing ethylene
diamine tetraacetic acid (EDTA) and centrifuged for 10 min
at 3000 rpm (41C) and the plasma removed for the enzymatic
calorimetric quantitation of FFA (NEFA C kit, Wako, Neuss,
Germany) and glycerol (Boehringer, Mannheim, Germany)
on a COBAS FARA centrifugal spectrometer (Roche Diagnos-
tica). Standard samples with known concentrations were
included in each run for quality control.
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Statistical analysis
All statistical calculations were performed with SPSS for
Macintosh (version 11.0; SPSS Inc., Chicago, IL, USA). The
initial statistical analysis, performed for the whole group
(n¼108), indicated a significant gender effect for the Arg16
allele on lipolytic parameters (iAUC DFFA; P¼0.01, allel–
gender interaction) and fat oxidation (iAUC DRQ; P¼0.042).
For this reason, the presented analysis is stratified by gender.
The effect of genotypes on lipolytic responses and fat
oxidation was investigated using analysis of variance
(ANOVA) (adjusted for age and BMI). Post hoc testing was
performed by Student’s unpaired t-test with Bonferroni
correction. Linkage disequilibrium was estimated according
to Devlin et al.37 Diplotype analysis were performed as
described before.38,39 The goodness of fit between observed
and expected genotype frequency (Hardy–Weinberg equili-
brium, HWE) was statistically tested using the w2-test.40
Allele and genotype frequency distributions for the whole
group (n¼ 108) are presented in Table 2. Energy expenditure
(EE) was adjusted for FFM by means of covariance analysis
(ANCOVA). The ISO-induced effect on fat oxidation (RQ),
thermogenesis (EE) and lipolysis (FFA, glycerol) were
expressed as incremental area under the curve (iAUC) above
baseline, calculated according to the trapezium rule. All data
are represented as mean7standard error of the mean
(s.e.m.). Po0.05 was considered as statistically significant.
Power calculation
A power analysis was performed to estimate the sample size
required enabling the accurate and reliable statistical judg-
ments for the two-way parametric statistics. There are little
or no published studies regarding the effect of ADRB2 and
GNB3 gene variants and whole body lipolysis and fat
oxidation, although the results of in vitro studies in human
adipocytes support a major effect. We therefore estimated
our sample size using published data of the effect of b-
adrenergic stimulation on whole body lipolysis and fat
oxidation.4,41,42 Power calculation indicated that to detect
a difference in circulating FFA of 100 mmol/l (with an s.d. of
50 mmol/l) or circulating glycerol of 50 mmol/l (with an s.d. of
25 mmol/l) and a power of 0.80 (a¼0.05 and b¼0.20), the
number of subjects in each group (two-tailed) should be 16.
Results
As mentioned under statistical methods, initial analysis
performed for the whole group (n¼108) indicated a
significant gender effect for the Arg16 allele. For this reason,
the presented analysis is stratified by gender.
Subjects
Anthropometric and metabolic characteristics of the study
subjects are shown in Table 1. Women had significantly
higher percentage body fat, a lower waist–hip ratio and were
significantly younger compared with male participants.
Additionally, women had a significantly higher fasting FFA
level. No significant differences were observed for BMI,
resting EE (adjusted for FFM) and fasting glycerol levels
between genders.
Effect of codon 16 and 27 of the b2-adrenoceptor gene (ADRB2)
on fat oxidation and lipolysis after b-adrenergic stimulation
Allele and genotype frequency distributions for the ADRB2
gene are shown in Table 2. For women, ANOVA analysis
Table 1 Subject characteristics
Men (n¼65) Women (n¼43) P-value
Age (year) 43.371.0 38.871.3 *
BMI (kg/m2) 32.570.5 32.370.6 NS
% body fat 31.770.7 42.470.7 **
WHR 1.0470.01 0.8670.02 **
EE resting (kJ/min) # 5.5670.10 5.7270.13 NS
RQ resting 0.8170.01 0.8270.01 NS
Fasting FFA (mmol/l) 477727 607730 **
Fasting glycerol (mmol/l) 7373 7777 NS
All values are means7s.e.m. Abbreviations: BMI, body mass index; EE, energy
expenditure; FFA, free fatty acids; RQ, respiratory quotient; WHR, waist-to-hip
ratio;,. # EE, adjusted for FFM. *P¼ 0.01, **Po0.001 men vs women using
Student’s unpaired t-test.
Table 2 Allele, genotype and diplotype frequency distributions of the ADRB2
gene and GNB3 gene polymorphisms
n¼108
Allele frequency
Arg16 0.394
Gln27 0.569
Thr164 0.972
C 0.741
Genotype frequency
Gly16Gly (wt) 0.371
Arg16Gly 0.472
Arg16Arg 0.157
Gln27Gln (wt) 0.352
Gln27Glu 0.435
Glu27Glu 0.213
Thr164Thr (wt) 0.944
Thr164Ile 0.056
Ile164Ile 0
CC 0.537
CT 0.407
TT 0.055
Diplotype frequency
Gly16Gly/Glu27Glu 0.185
Gly16Gly/Gln27Gln 0.018
Arg16Arg/Gln27Gln 0.148
Alleles, genotypes and diplotypes are presented as decimals. All SNPs were in
HWE. Abbreviations: Arg, arginine; Gln, glutamic acid; Glu, glutamine; Gly,
glycine; Ile, isoleucine; Thr, threonine; wt, wild type.
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indicated a significant genotype effect for codon 16 and a
blunted increase in FFA (P¼0.046, see Figure 1), glycerol
(P¼ 0.037, see Figure 1) and fat oxidation (P¼0.042, see
Figure 2), even after correction for age and BMI. Post hoc
analysis indicated that in women the Arg16Gly geno-
type was significantly associated with a blunted increase
in circulating FFA (iAUC DFFA after ISO: 379735 vs
493740 mmol/l, P¼0.041, see Figure 1) and glycerol (iAUC
DGlycerol after ISO: 86711 vs 128714 mmol/l, P¼0.026, see
Figure 1) during stimulation compared with female Gly16
homozygotes. In addition to a blunted lipolytic response,
female Arg16Gly heterozygotes showed a blunted increase in
fat oxidation compared with Gly16 homozygotes (iAUC DRQ
after ISO: 0.00470.007 vs –0.01770.008, P¼0.043, see
Figure 2) and a comparable thermogenic response (iAUC
DEE after ISO: 0.5170.07 vs 0.7070.09 kJ/min, NS).
Because lipolytic response and fat oxidation appeared to be
reduced in both Arg16Gly and Arg16Arg carriers, Arg16
heterozygotes and homozygotes were combined into one
group (Arg16GlyþArg16Arg). Female Arg carriers (Arg16-
GlyþArg16Arg) appeared to have a blunted increase in
circulating FFA (382731 vs 493743 mmol/l, P¼0.042)
and glycerol (89710 vs 129718 mmol/l, P¼0.038) after
b-adrenergic stimulation compared with Gly16Gly homo-
zygotes. This altered lipolytic response in female Arg carriers
(Arg16GlyþArg16Arg) was accompanied by a decreased
fat oxidation after stimulation (iAUC DRQ after ISO
0.00370.007 vs 0.01670.005, P¼0.024). No differences
were found in ISO-induced thermogenesis (iAUC DEE after
ISO: 0.5770.07 vs 0.7070.09 kJ/min, NS), body weight, BMI
and other anthropometric variables.
Data in male overweight subjects were less consistent:
ANOVA analysis (adjusted for age and BMI) indicated only a
significant genotype effect of codon 16 and a blunted
increase in FFA (P¼ 0.022, see Figure 1). Post hoc analysis
revealed that male carriers of the Arg16Gly genotype had a
significantly blunted increase in circulating FFA during b-
adrenergic stimulation compared with male Gly16 homo-
zygotes, (266730 vs 401734 mmol/l, P¼0.005; see Figure 1).
However, this blunted FFA response was not accompanied by
a blunted increase in circulating glycerol (see Figure 1) nor a
decreased fat oxidation (iAUC DRQ, see Figure 2). Further-
more, taking Arg16 heterozygotes and homozygotes
together into one group, (Arg16GlyþArg16Arg) carriers
showed a blunted increase in circulating FFA (281721 vs
406741 mmol/l, P¼0.004) compared with Gly16Gly carriers,
whereas ISO-induced changes in glycerol, thermogenesis and
RQ were comparable between groups. Again, no differences
were found in body weight, BMI and other anthropometric
variables.
For neither female nor male subjects associations were
found between genetic variation in codon 27 and 164 of the
b2-adrenoceptor gene (ADRB2) and alterations in fat oxida-
tion or lipolytic response during b-adrenergic stimulation.
Diplotype analysis
Three homozygous and functional diplotypes were investi-
gated in both male and female subjects: Gly16Gly/Glu27Glu,
Arg16Arg/Gln27Gln and Gly16Gly/Gln27Gln. The diplotype
frequency distribution is depicted in Table 2. From the 55
men carrying the Gly16 allele, 47 also carried the Glu27
allele (w2¼32.653, Po0.0001), indicating linkage disequili-
brium (|D0‘|¼0.854, r2¼0.494).37 In 21.5% (n¼14) of the
men and 14% (n¼6) of the women, the Gly16Gly/Glu27Glu
diplotype was apparent. This diplotype was not associated
with a decreased lipolytic response (iAUC DFFA and iAUC
Dglycerol) or fat oxidation (iAUC DRQ) in male or female
Figure 1 Lipolytic response for codon 16 polymorphisms of the ADRB2
gene. All values are means7s.e.m. iAUC DFFA, iAUC Dglycerol: incremental
area under the curve for circulating free fatty acid (FFA) or glycerol
concentration during b-adrenergic stimulation. G16G: Gly16Gly (black bar),
A16G: Arg16Gly (gray bar), A16A: Arg16Arg (white bar). ANOVA (adjusted for
age and BMI): #P¼0.022, ##P¼ 0.046, ###P¼ 0.037. Post hoc Student’s
unpaired t-test: *P¼ 0.005, **P¼ 0.041, ***P¼ 0.026 A16G vs G16G. Number
of subjects in each group is indicated in the bars.
Figure 2 Fat oxidation for codon 16 polymorphisms of the ADRB2 gene. All
values are means7s.e.m. iAUC DRQ: Incremental area under the curve for
delta respiratory quotient (RQ) during b-adrenergic stimulation. G16G:
Gly16Gly (black bar), A16G: Arg16Gly (gray bar), A16A: Arg16Arg (white
bar). ANOVA (adjusted for age and BMI): #P¼0.042. Post hoc Student’s
unpaired t-test: *P¼0.043 G16G vs A16G. Number of subjects in each group
is indicated in the bars.
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subjects. Nevertheless, female carriers (n¼6) of the
Gly16Gly/Glu27Glu diplotype had lower fasting FFA levels
(431749 vs 636732 mmol/l, Po0.05) compared with female
non-carriers (n¼37). No differences were found in body
weight, BMI and other anthropometric variables. The
other two diplotypes (Arg16Arg/Gln27Gln and Gly16Gly/
Gln27Gln) were also not associated with an altered fat
oxidation, thermogenic or lipolytic response in this popula-
tion. Owing to the relatively low sample size, we were not
able to identify b2-adrenoceptor haplotypes for codons 16,
27 and 164 with a frequency 45%.
Effect of the C825T polymorphism in exon 10 of the G protein
beta-3 subunit (GNB3) gene on fat oxidation and lipolysis
Allele and genotype frequency distributions for the GNB3
gene are shown in Table 2. Male TT carriers (n¼4) showed a
tendency toward a blunted increase in circulating FFA (iAUC
DFFA after ISO: 173746 vs 435732 mmol/l) and glycerol
(iAUC DGlycerol after ISO: 47714 vs 10778 mmol/l) after
b-adrenergic stimulation compared with CT carriers (n¼29).
Similar results were obtained for male CC carriers (n¼32).
Unfortunately, the number of subjects in the TT group
(n¼4) were too small to perform statistical analysis. In
female overweight subjects, no associations were found for
the C825T polymorphism and an altered lipolytic response,
thermogenesis or fat oxidation.
Discussion
To the best of our knowledge, this is the first study to
investigate the association between genetic variability in the
ADRB2 gene and GNB3 gene and in vivo lipolysis and fat
oxidation in overweight and obese men and women.
The major findings of our study are as follows: firstly,
genetic variability in codon 16 of the ADRB2 gene was
associated with a blunted increase in circulating FFA and
glycerol during b-adrenergic stimulation with the non-
selective ISO in female subjects. In male subjects, codon 16
was associated with a blunted ISO-induced increase in FFA,
whereas no difference in glycerol was apparent. In female
subjects, this blunted lipolytic response was also accompa-
nied with a reduced fat oxidation. Finally, the TT genotype of
the GNB3 gene was associated with a blunted increase in FFA
and glycerol in male subjects. This blunted lipolytic response
was not accompanied by a reduced fat oxidation.
Large et al.16 showed that the Arg16Gly genotype was
associated with an in vitro fivefold increase in agonist
sensitivity of the b2-adrenoceptor in abdominal subcuta-
neous adipocytes of overweight female subjects, without any
significant effect on glycerol release. In our study, the Arg16
allele was associated with blunted ISO-induced responses in
FFA, glycerol and fat oxidation (iAUC DRQ) in women and a
blunted increase in FFA in men. The reason for this apparent
discrepancy with our findings may be related to the
differences in our in vivo vs the in vitro approach to study
lipolysis. In the in vitro situation, in vivo factors like the
neuroendocrine environment and local adipocyte blood
flow are not taken into account. In addition, the majority
of in vitro studies are performed on adipocytes derived from
the subcutaneous region in both genders. It should be
mentioned that there are major differences in catechola-
mine-induced lipolysis between depots (subcutaneous vs
visceral and gluteofemoral) and also gender differences in
body fat distribution.43–45 Our data indicate that variability
in codon 16 of the ADRB2 gene may contribute to a reduced
in vivo b-adrenoceptor-mediated lipolysis and fat oxidation,1–4
indicating that these blunted responses may be important
primary factors in obesity.
Besides looking at individual codons, we also studied
the effect of diplotypes. We chose to study two common
(410% in the population) and one less common (o5%)
homozygous combination (Gly16Gly/Glu27Glu, Arg16Arg/
Gln27Gln and Gly16Gly/Gln27Gln), as they have been
reported to have a significant effect on lipolysis.38 In
addition, these SNPs belong to the same pathway and
transfection experiments showed that they are functional.39
Finally, in our population, as has been reported before, there
is strong linkage disequilibrium between codons 16 and 27.46
Nevertheless, no effect of diplotypes on lipolytic, thermo-
genic response or fat oxidation was found in our study.
Only the Gly16Gly/Glu27Glu diplotype was associated
with a lower fasting FFA concentration in female over-
weight subjects, which may possibly reflect a reduced
rate of lipolysis in subcutaneous adipose tissue.47 Finally,
literature suggests that the Thr164Ile b2-adrenoceptor
polymorphism is closely associated with Gly at position
16 and Gln at position 27.39,48 Nevertheless, due to the
relatively low sample size, we were not able to identify
b2-adrenoceptor haplotypes for codons 16, 27 and 164 with a
frequency 45%.38
The observed genotype frequency for the polymorphism
in the GNB3 gene was similar to that previously reported in
other Caucasian populations.26,31 Ryde´n et al.35 showed that
the T variant of this polymorphism was associated with a
blunted in vitro responsiveness for the non-selective ISO in
abdominal subcutaneous adipocytes of male and female
overweight subjects. In contrast with Ryden et al.35 we found
a tendency toward a reduced lipolysis aney in male over-
weight subjects. It should be mentioned that our sample has
no adequate power to provide a conclusive result about a
genotype effect for the C825T polymorphism in the GNB3
gene. Thus, further studies are necessary to confirm our in
vivo findings in a larger population.
In summary, variation in codon 16 of the ADRB2 gene is
associated with an impaired lipolytic response in male and
female overweight and obese subjects and by a blunted fat
oxidation in overweight and obese women. In conclusion,
the present results suggest that genetic variability in the
ADRB2 gene influences lipolysis regulation in vivo in over-
weight and obese subjects and that this is subject to gene–
ADRB2 gene in obesity
JWE Jocken et al
817
International Journal of Obesity
gender interactions. This indicates that genetic variability
in the ADRB2 gene may be an important factor in the
development or progression of obesity and obesity-related
disorders.
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